Harpoon Therapeutics, Inc. (HARP) financial statements (2021 and earlier)

Company profile

Business Address 131 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:15589
Cash and cash equivalents8989
Short-term investments59 
Other undisclosed cash, cash equivalents, and short-term investments7 
Other undisclosed current assets(4)1
Total current assets:15190
Noncurrent Assets
Operating lease, right-of-use asset7
Property, plant and equipment113
Long-term investments and receivables7 
Long-term investments7 
Other noncurrent assets14
Other undisclosed noncurrent assets 6
Total noncurrent assets:2612
TOTAL ASSETS:177103
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities108
Accounts payable34
Accrued liabilities73
Deferred revenue11
Debt1 
Contract with customer, liability4
Total current liabilities:2312
Noncurrent Liabilities
Long-term debt and lease obligation14 
Operating lease, liability14
Liabilities, other than long-term debt4615
Deferred revenue46
Contract with customer, liability8
Other liabilities 7
Total noncurrent liabilities:6015
Total liabilities:8226
Temporary equity, carrying amount 130
Stockholders' equity
Stockholders' equity attributable to parent94(53)
Common stock00
Additional paid in capital2129
Accumulated other comprehensive income0 
Accumulated deficit(118)(63)
Total stockholders' equity:94(53)
TOTAL LIABILITIES AND EQUITY:177103

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:65
Operating expenses(64)(32)
Operating loss:(58)(28)
Nonoperating income30
Investment income, nonoperating30
Loss before gain (loss) on sale of properties:(55)(27)
Other undisclosed net loss(1) 
Net loss available to common stockholders, diluted:(56)(27)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(56)(27)
Other comprehensive income0 
Comprehensive loss, net of tax, attributable to parent:(56)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: